Pulse Biosciences (NASDAQ:PLSE) Sees Strong Trading Volume – Here’s Why

Shares of Pulse Biosciences, Inc (NASDAQ:PLSE) saw strong trading volume on Monday . 248,495 shares were traded during mid-day trading, a decline of 13% from the previous session’s volume of 284,261 shares.The stock last traded at $21.1950 and had previously closed at $20.75.

Wall Street Analyst Weigh In

PLSE has been the subject of several research analyst reports. Mizuho set a $30.00 target price on shares of Pulse Biosciences in a report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Pulse Biosciences presently has a consensus rating of “Hold” and a consensus target price of $26.00.

Pulse Biosciences Stock Up 16.7%

The firm has a market capitalization of $1.64 billion, a price-to-earnings ratio of -21.42 and a beta of 1.77. The company’s 50 day moving average is $14.29 and its 200 day moving average is $15.46.

Institutional Investors Weigh In On Pulse Biosciences

Several institutional investors have recently made changes to their positions in the stock. AlphaQuest LLC grew its stake in Pulse Biosciences by 184.5% during the second quarter. AlphaQuest LLC now owns 8,864 shares of the company’s stock worth $134,000 after buying an additional 5,748 shares in the last quarter. Inspire Investing LLC lifted its stake in Pulse Biosciences by 19.7% during the second quarter. Inspire Investing LLC now owns 25,891 shares of the company’s stock worth $391,000 after purchasing an additional 4,267 shares during the last quarter. Westside Investment Management Inc. lifted its stake in Pulse Biosciences by 10.5% during the second quarter. Westside Investment Management Inc. now owns 64,290 shares of the company’s stock worth $970,000 after purchasing an additional 6,135 shares during the last quarter. Creative Planning boosted its holdings in shares of Pulse Biosciences by 26.3% in the 2nd quarter. Creative Planning now owns 18,971 shares of the company’s stock valued at $286,000 after purchasing an additional 3,951 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Pulse Biosciences in the 2nd quarter valued at $302,000. 76.95% of the stock is currently owned by institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.